[6] Janjigian YY, Kawazoe A, Bai Y, Xu J, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER-2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023 :S0140-6736(23)02033-0. ...
[6] Janjigian YY, Kawazoe A, Bai Y, Xu J, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER-2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 ran...
KEYNOTE-811研究为HER2阳性不可切除胃癌的一线治疗奠定了新的标准,而DESTINY-Gastric03研究中的T-DXd联合治疗展现了新的抗肿瘤潜力,但仍需进一步研究以评估其长期安全性和有效性。这两项研究标志着HER2靶向治疗在胃癌领域的又一重大进展,未...
KEYNOTE-811研究，HER2阳性人群，胃癌一线，帕博利珠单抗联合曲妥珠单抗加化疗对比曲妥珠单抗加化疗，在早先公布的数据中表现出获益趋势，且较为惊艳。2023年6月16日，默沙东宣布Keytruda+曲妥珠单抗+化疗联合一线治疗HER2阳性胃癌的三期临床KEYNOTE-811在中期分析中达到PFS主要终点。不过，该三期临床在总生存期（OS）方面有...
KEYNOTE-811 研究是全球首个探索免疫治疗联合靶向治疗和化疗一线治疗 HER-2 阳性晚期胃癌免疫治疗 III 期临床研究,2021 年美国临床肿瘤学会(ASCO)年会上,KEYNOTE-811 研究公布的第一阶段的分析结果(IA1)[4]显示,帕博利珠单抗+曲妥珠单抗+化疗组的 ORR 达到 74.4%,较安慰剂+曲妥珠单抗+化疗组提高了 22.7%。基于...
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei ...
Clinical trial registration:NCT03615326(ClinicalTrials.gov). HER2阳性晚期胃癌患者的治疗选择有限,这些患者的预后较差。Pembrolizumab 作为单一疗法、联合化疗和联合曲妥珠单抗,已在晚期胃或胃食管结合部腺癌患者中显示出有希望的抗肿瘤活性。因此,将派姆单抗与曲妥珠单抗和化学疗法相结合可能会为晚期HER2阳性胃癌患者带来...
placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registra...
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer 喜欢 0 阅读量: 322 作者:YY Janjigian,A Kawazoe,P Yaez,N Li,S Lonardi,O Kolesnik,O Barajas,Y Bai,L Shen,Y Tang 摘要: Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) ...
In KEYNOTE-811, when KEYTRUDA was administered in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 6% of 217 patients with locally advanced unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma. The most co...